149902-05-6

Upstream product

• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 108-94-1 cyclohexanone 
• 22524-46-5 cyclohex-1-en-1-yl 4-methylbenzenesulfonate 
• 66107-33-3 3-methoxyphenyl triflate 
• 110-83-8 cyclohexene 
• 150-19-6 O-methylresorcine 
• 2398-37-0 3-methoxyphenyl bromide 
• 28075-50-5 cyclohex-1-en-1-yl trifluoromethane sulfonate 
• 38111-44-3 phenylzinc(II) bromide 
• 181705-90-8 (3-methoxyphenyl)zinc(II) bromide 
• 1884-42-0 1-(m-Methoxyphenyl)cyclohexanol 

Downstream Products

• 41876-58-8 1-cyclohexyl-3-methoxybenzene 
• 105911-71-5 3-(2-nitro-cyclohex-1-enyl)-anisole 
• 93427-57-7 2-Nitro-1-m-anisyl-cyclohexen-⁽¹⁾-on-⁽⁶⁾-oxim 
• 32960-79-5 3-(1-cyclohexen-1-yl)phenol 
• 43050-31-3 2-(3-methoxyphenyl)cyclohex-2-en-1-ol 
• 93257-72-8 2-Nitro-1-m-anisyl-cyclohexen-⁽¹⁾-on-⁽⁶⁾ 
• 541505-88-8 (S,S)-1-(3-Methoxy-phenyl)-7-oxa-bicyclo[4.1.0]heptane 
• 1269246-98-1 6-benzyloxy-1-(3-methoxyphenyl)cyclohexene 
• 1321159-56-1 6-(4-nitrophenylamino)-1-(3-methoxyphenyl)cyclohexene 
• 56231-51-7 3-(3-methoxyphenyl)cyclohex-2-en-1-one 
• 43050-17-5 (+/-)-1-(3-Methoxy-phenyl)-7-oxa-bicyclo[4.1.0]heptane 
• 1943-95-9 meta-cyclohexylphenol 

Relevant academic research and scientific papers

Synthesis of methoxetamine, its metabolites and deuterium labelled analog as analytical standards and their HPLC and chiral capillary electrophoresis separation

Methoxetamine, a designer drug marketed as a replacement for the dissociative anaesthetic ketamine, has been associated with significant numbers of hospital related intoxications and deaths in Europe. The fast and user-friendly identification and quantification of methoxetamine and its metabolites is a key factor for successful treatment of intoxication. Therefore, we suggested a convenient preparation method which was used for the synthesis of methoxetamine, seven methoxetamine metabolites and a deuterium labelled derivative as analytical standards. Methoxetamine and normethoxetamine were used as starting materials for the preparation of O-demethylated and N-dealkylated metabolites. The multistep synthesis starts from commercially available compounds and offers good yields. Our prepared analytical standards were used for the confirmation of the suggested structure of methoxetamine metabolites in rat urine by LCMS. Capillary electrophoresis was used for the chiral separation of MXE and its metabolites using β-cyclodextrin, carboxymethylated β-cyclodextrin, and sulphated β-cyclodextrin as chiral selectors at various concentrations. Chiral separation was successful for four analytes. A mixture of MXE and its metabolites was subsequently analyzed under optimal conditions, i.e. when using 15 mmol L-1 β-cyclodextrin in 50 mmol L-1 phosphate buffer, pH 2.5. In this case, chiral separation was achieved for three analytes and all analytes were separated from each other.

Achieving vinylic selectivity in Mizoroki-heck reaction of cyclic olefins

In Heck reactions of cyclic olefins, the products usually have aryl groups that end up at the allylic and/or homoallylic position. We herein report new selectivity that adds aryl groups to the vinylic position. Cyclic olefins of various ring size worked well. The desired isomers were produced by palladium-hydride-catalyzed isomerization of the initial products. Thus, a specific catalyst must be used so that it can perform two jobs under one set of reaction conditions. Copyright

FeCl3/Nal-catalyzed allylic C-H oxidation of arylalkenes with a catalytic amount of disulfide under air

This paper describes a FeCl3/NaI-catalyzed formal allylic C-H oxidation of arylalkenes using a catalytic amount of disulfide with BnOH and 4-nitroaniline as nucleophiles and air as oxidant to form the corresponding allyl ethers and amines. A possible reaction mechanism has been proposed.

Well-defined air-stable palladium HASPO complexes for efficient Kumada-Corriu cross-couplings of (Hetero)aryl or alkenyl tosylates

Palladium complexes of representative heteroatom-substituted secondary phosphine oxide (HASPO) preligands were synthesized and fully characterized, including X-ray crystal structure analysis. Importantly, these well-defined complexes served as highly efficient catalysts for Kumada-Corriu cross-coupling reactions of aryl, alkenyl, and even heteroaryl tosylates. Particularly, an air-stable catalyst derived from inexpensive PinP(O)H displayed a remarkably high catalytic efficacy, which resulted in cross-couplings at low catalyst loadings under exceedingly mild reaction conditions with ample scope.

COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS

Disclosed herein are methods of treating neuropathic pain, reducing inflammation, reducing IL-4 levels, and reducing IFN-γ levels, using various di-aromatic compounds for use as estrogen receptors β agonists.

COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS

Disclosed herein are novel di-phenyl compounds and methods for using various di-phenyl compounds for treatment and prevention of diseases and disorders related to estrogen receptors.

Tramadol analogs and uses thereof

Compounds of formula I are effective in treating disorders modulated by opiate receptor activity and/or monoamine activity. In formula I, R1 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl; R2 is selected from hydrogen, hydroxy, cyano, haloalkyl, glycosyl, SO2R5, and OR5; R3 and R4 are independently selected from hydrogen and lower alkyl, or R3 and R4 taken together with nitrogen form a five- or six-membered heterocyclic or substituted heterocyclic ring; and R5 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl.